DR REDDY'S : SEP-QTR LICENSE INCOME INCLUDES RS 97.6 CR RUSSIA BIOSIMILAR MILESTONES

License and service income for the quarter ended September 30, 2026 also includes ₹52.9 Cr from sale of US territorial rights relating to Bendamustine HCL. Impact: Highlights milestone and territorial-rights income within quarterly license and service revenue.

Dr Reddys Laboratories Ltd

Open attachment

← Back to feed